Novo Nordisk, one of the principal suppliers of GLP-1 weight-loss medication, has handed a board role to the chief executive of Mars. Poul Weihrauch is to be a “board observer” at the pharma group, which markets GLP-1 drugs under brands including Ozempic and Wegovy. GLP-1 medication, associated with appetite suppression, was first approved to treat Type-2 diabetes in the US more than 15 years ago and for the treatment of obesity around a decade ago. However, with more consumers turning to the drugs to ...